Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164,729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Meng FY, Gao F, Jia SY, Wu XH, Li JX, Guo XL, Zhang JL, Cui BP, Wu ZM, Wei MW, Ma ZL, Peng HL, Pan HX, Fan L, Zhang J, Wan JQ, Zhu ZK, Wang XW, Zhu FC. Meng FY, et al. Among authors: zhang jl, zhang j. Signal Transduct Target Ther. 2021 Jul 15;6(1):271. doi: 10.1038/s41392-021-00692-3. Signal Transduct Target Ther. 2021. PMID: 34267185 Free PMC article. Clinical Trial.
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.
He Q, Mao Q, Peng X, He Z, Lu S, Zhang J, Gao F, Bian L, An C, Yu W, Yang F, Zhou Y, Yang Y, Li Y, Yuan Y, Yan X, Yang J, Wu X, Huang W, Li C, Wang J, Liang Z, Xu M. He Q, et al. Among authors: zhang j. Signal Transduct Target Ther. 2022 Mar 3;7(1):69. doi: 10.1038/s41392-022-00926-y. Signal Transduct Target Ther. 2022. PMID: 35241645 Free PMC article.
164,729 results
You have reached the last available page of results. Please see the User Guide for more information.